Oncology - NRAS, KRAS, BRAF
Cidegen
Delivery time
No especificado
Sample
No especificado
490,00€
Detection of the most common mutations in the NRAS, BRAF, and KRAS genes. Tumors harboring these mutations have been shown to respond less well to anti-EGFR therapies. Therefore, it is necessary to study these mutations to identify patients who may be resistant to anti-EGFR therapies.
Other tests
Trisomy 11 (Blood. Biopsy tissue)
166,98€
Trisomy 11 (Blood. Biopsy tissue. Bone marrow)
166,98€
Sequencing of exons 9, 11, 13 and 14 of the POLE gene. (Analysis in biopsy tissue)
932,31€